Immunization and Multiple Sclerosis Clinical Practice Guidelines (AAN, 2019)

American Academy of Neurology

This is a quick summary of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

October 08, 2019

Guidelines for vaccine-preventable infections and immunization in multiple sclerosis were published in 2019 by the American Academy of Neurology (AAN).[1]

Discuss the evidence regarding immunizations in MS with patients.

Recommend that MS patients follow all local vaccine standards, unless there are specific contraindications.

Recommend annual influenza vaccination to MS patients.

Counsel MS patients about infection risks associated with specific immunosuppressive/ immunomodulating (ISIM) medications and treatment-specific vaccination guidance according to prescribing information (PI).

Vaccinate patients with MS as needed at least 4–6 weeks before initiating ISIM therapy.

Screen for infections according to PI before initiating ISIM medications and treat patients testing positive for latent infections.

Screen for latent infections in high-risk populations before starting ISIM therapy even when not specifically mentioned in PI.

Recommend against using live-attenuated vaccines in MS patients receiving ISIM therapies.

Delay vaccination in MS patients experiencing a relapse.

For more Clinical Practice Guidelines, go to Guidelines.

For more information, go to Multiple Sclerosis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.